Clinical Characteristics, Disease Activity, Functional Status, and Quality of Life Results of Patients With Psoriatic Arthritis Using Biological and Conventional Synthetic Disease-Modifying Antirheumatic Drugs

Keskin, Yaşar; Nas, Kemal; Kılıç, Erdem; Sargın, Betül; Kasman, Sevtap Acer; Alkan, Hakan; Şahin, Nilay; Cengiz, Gizem; Cüzdan, Nihan; Gezer, İlknur Albayrak; Keskin, Dilek; Mülkoğlu, Cevriye; Reşorlu, Hatice; Ataman, Şebnem; Bal, Amanjit; Duruöz, Mehmet Tuncay; Küçükakkaş, Okan; Yurdakul, Ozan Volkan; Melikoğlu, Meltem Alkan; Aydin, Yıldıray; Ayhan, Fi̇kri̇ye Fi̇gen; Bodur, Hatice; Çalış, Mustafa; Çapkın, Erhan; Devrimsel, Gül; Gök, Kevser; Hizmetli, Sami; Kamanlı, Ayhan; Ecesoy, Hilal; Kutluk, Öznur; Şen, Nesrin; Şendur, Ömer Faruk; Tekeoğlu, İbrahim; Tolu, Sena; Toprak, Murat; Tuncer, Tiraje

doi:10.46497/archrheumatol.2021.7874

Cited by 5 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, biologics are the only drugs that have shown their effectiveness in reducing and/or blocking the articular damage, thus preventing PsA progression [29][30][31] where traditional systemic therapies, including cyclosporine or methotrexate, have been shown to be not effective [32,33].…”

Section: Discussionmentioning

confidence: 99%

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

et al. 2021

View full text Add to dashboard Cite

Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Depending on the disease severity and surface area involvement, the adjusted total scores ranging from zero to 72 were calculated for each patient. Higher scores indicate more severe psoriatic conditions [ 26 , 27 ].…”

Section: Methodsmentioning

confidence: 99%

Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry

Duruöz,

Bodur,

Ataman

et al. 2024

Rheumatol Int

Self Cite

View full text Add to dashboard Cite

The association between spondyloarthritis and cardiovascular (CV) diseases is complex with variable outcomes. This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. The prevalence rate of CV disease was 3.0% in patients with spondyloarthritis. Hypertension, dyslipidemia, and cancer history were the independent CV risk factors for CV disease in patients with spondyloarthritis.

show abstract

“…IIDs are also used in chronic conditions of the bowels19–21 (eg, Crohn’s disease, ulcerated colitis, diverticulitis) as well as for antirejection therapy22 when organ transplants or grafts have been used as they suppress the autoimmune destruction. These medicines are important because they provide a lifeline towards functional mobility and improves the quality of life23 24 for patients by relieving their pain as well as retarding disease progression. Other medicines include alkylating agents (eg, cyclophosphamide), Janus kinase inhibitors (eg, baricitinib), phosphodiesterase type-4 inhibitor (eg, apremilast) and tumour necrosis factor—alpha inhibitor (eg, adalimumab (Humira), etanercept (Enbrel)) are used for RA.…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset

Barrett

Lin

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo investigate monthly prescription refills for common immunosuppressive/immunomodulatory therapy (sulfasalazine, hydroxychloroquine, azathioprine, methotrexate, leflunomide) prescriptions in England during the complete first wave of the COVID-19 pandemic. Secondary analysis examined unit cost analysis and regional use.Design and settingA national cohort of community-based, primary care patients who anonymously contribute data to the English Prescribing Dataset, dispensed in the community in England, were included. Descriptive statistics and interrupted time series analysis over 25 months (14 months before, 11 months after first lockdown) were evaluated (January 2019 to January 2021, with March 2020 as the cut-off point).Outcome measuresPrescription reimbursement variance in period before the pandemic as compared with after the first lockdown.ResultsFluctuation in monthly medicines use is noted in March 2020: a jump is observed for hydroxychloroquine (Mann-Whitney, SE 14.652, standardised test statistic 1.911, p value=0.059) over the study period. After the first lockdown, medicines use fluctuated, with wide confidence intervals. Unit-cost prices changed substantially: sulfasalazine 33% increase, hydroxychloroquine 98% increase, azathioprine 41% increase, methotrexate 41% increase, leflunomide 20% decrease. London showed the least quantity variance, suggesting more homogeneous prescribing and patient access compared with Midlands and East of England, suggesting that some patients may have received medication over/under requirement, representing potential resource misallocation and a proxy for adherence rates. Changepoint detection revealed four out of the five medicines’ use patterns changed with a strong signal only for sulfasalazine in March/April 2020.ConclusionsFindings potentially present lower rates of adherence because of the pandemic, suggesting barriers to care access. Unit price increases are likely to have severe budget impacts in the UK and potentially globally. Timely prescription refills for patients taking immunosuppressive/immunomodulatory therapies are recommended. Healthcare professionals should identify patients on these medicines and assess their prescription-day coverage, with planned actions to flag and follow-up adherence concerns in patients.

show abstract

Clinical Characteristics, Disease Activity, Functional Status, and Quality of Life Results of Patients With Psoriatic Arthritis Using Biological and Conventional Synthetic Disease-Modifying Antirheumatic Drugs

Cited by 5 publications

References 39 publications

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?

Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry

Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset

Contact Info

Product

Resources

About